目的 评价经门静脉自体骨髓干细胞移植治疗失代偿期肝硬化的疗效及安全性.方法 将38例患者随机分为观察组18例和对照组20例.对照组予以基础治疗,观察组在基础治疗上经门静脉注入自体骨髓干细胞治疗.结果 治疗后第3天,观察组有15例(83.3%)患者乏力、纳差症状改善,对照组有2例(10.0%)改善,组间差异显著(P<0.05);治疗后8周,观察组腹水消退10例(55.5%),腹胀减轻16例(88.9%),对照组分别为2例 (10.0%)和6例(30.0%),差异明显(P<0.05);治疗组和对照组ALB水平分别为34.4±8.7g/L和26.3±7.5g/L;PTA分别为45.6±10.3%和37.4±9.3%,差异均显著(P<0.05).所有患者均未出现严重不良反应.结论 经门静脉进行自体骨髓干细胞移植治疗失代偿期肝硬化疗效明显、安全性好.%Objective To evaluate the curative effect and safety of auto-marrow stem cell transplantation through portal vein in treatment of patients with decompensated liver cirrhosis. Methods 38 patients with decompensated liver cirrhosis were randomly divided into transplantation group (n=18)and control group (n=20). Results Clinical symptoms such as fatigue and poor appetite were ameliorated obviously three days after transplantation in 15 cases(83.3％), while only two cases (1 0.0％)in control group;There were 10 patients (55.5％) with ascites, and 16 (88.9％)with abdominal distention disappeared in transplantation group, while only two cases (10％)and six cases (30％)respectively in control group (P＜0.05) ;The level of albumin was 34.4±8.7g/L in transplantation group,much higher than that in control group (26.3±7.5g/L)8 weeks latter, and the prothrombin time activity was 45.6±10.3％ and 37.4±9.3％ respectively in the two groups (P＜0.05). No adverse reaction and complications were observed in all patients. Conclusion Auto-marrow stem cells transplantation through portal vein in treatment of patients with decompensated liver cirrhosis is effective and safe.
展开▼
